

*Financial Statements of*

**BIOSCIENCE ENTERPRISE CENTRE INCORPORATED**

*March 31, 2011*

## Independent Auditor's Report

To the Board of Directors of  
BioScience Enterprise Centre Incorporated

Tel: (902) 422-8541  
Fax: (902) 423-5820  
www.deloitte.ca

We have audited the accompanying financial statements of Bioscience Enterprise Centre Incorporated ("the Corporation"), which comprise the balance sheet as at March 31, 2011, and the statements of loss and deficit, and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

### *Management's Responsibility for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian generally accepted accounting principles, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

### *Auditor's Responsibility*

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Opinion*

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Corporation as at March 31, 2011, and the results of its operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles.

*Deloitte & Touche LLP*

Chartered Accountants  
Halifax, Nova Scotia  
June 29, 2011

# **BIOSCIENCE ENTERPRISE CENTRE INCORPORATED**

## **Table of Contents**

**March 31, 2011**

---

	<u>Page</u>
Balance Sheet	1
Statement of Loss and Deficit	2
Statement of Cash Flows	3
Notes to the Financial Statements	4-8

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Balance Sheet

As at March 31, 2011

	2011	2010
<b>ASSETS</b>		
Cash	\$ 30,515	\$ 44,731
Receivables	43,167	34,220
Property and equipment (Note 4)	23,870	26,488
	<u>\$ 97,552</u>	<u>\$ 105,439</u>
<b>LIABILITIES</b>		
Payables and accrued liabilities	\$ 17,258	\$ 25,598
Due to Innovacorp	805,273	538,077
Deferred government contributions	16,818	22,530
	<u>839,349</u>	<u>586,205</u>
<b>SHAREHOLDERS' DEFICIENCY</b>		
Capital stock (Note 6)	1	1
Deficit	(741,798)	(480,767)
	<u>(741,797)</u>	<u>(480,766)</u>
	<u>\$ 97,552</u>	<u>\$ 105,439</u>

ON BEHALF OF THE BOARD

..... Director

..... Director

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Statement of Loss and Deficit

Year ended March 31, 2011

	2011	2010
Revenues		
Rent	\$ 285,651	\$ 280,960
Amortization of government contributions	5,712	11,399
Business services	126,074	107,035
Other	4,192	4,434
	<u>421,629</u>	<u>403,828</u>
Expenses		
Advertising and promotion	567	208
Bad debts	82,363	29,496
Communications	27,982	24,489
Amortization	5,712	6,671
Information resources	251	586
Interest and bank charges	269	211
Materials	11,888	10,858
Miscellaneous	25,547	4,337
Outside services	33,598	21,590
Professional development	1,956	3,030
Rent	120,055	100,814
Repairs and maintenance	34,552	52,044
Salaries and benefits	217,046	220,950
Travel	4,565	5,509
Utilities	116,309	103,612
	<u>682,660</u>	<u>584,405</u>
Net loss	(261,031)	(180,577)
Deficit, beginning of year	(480,767)	(300,190)
Deficit, end of year	\$ (741,798)	\$ (480,767)

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Statement of Cash Flows

Year ended March 31, 2011

	2011	2010
<b>INCREASE (DECREASE) IN CASH</b>		
Operating		
Net loss	\$ (261,031)	\$ (180,577)
Items not affecting cash:		
Amortization	5,712	6,671
Amortization of government contributions	(5,712)	(11,399)
	(261,031)	(185,305)
Changes in non-cash operating working capital		
Receivables	(8,947)	35,718
Inventory	-	4,839
Payables and accrued liabilities	(8,340)	28,291
Deferred revenue	-	(19,768)
	(278,318)	(136,225)
Investing		
Purchases of property and equipment	(3,094)	(1,109)
Financing		
Due to Innovacorp	267,196	126,017
<b>DECREASE IN CASH</b>	<b>(14,216)</b>	<b>(11,317)</b>
<b>CASH, BEGINNING OF YEAR</b>	<b>44,731</b>	<b>56,048</b>
<b>CASH, END OF YEAR</b>	<b>\$ 30,515</b>	<b>\$ 44,731</b>

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Notes to the Financial Statements

March 31, 2011

---

### 1. NATURE OF OPERATIONS

BioScience Enterprise Centre Incorporated (the "Corporation") developed and leased an incubation facility to be a catalyst for the bio-life science industry sector. The Corporation is exempt from income taxes under Section 149 of the *Income Tax Act*.

### 2. FUTURE ACCOUNTING CHANGES

#### *New accounting framework*

In December 2009, the Public Sector Accounting Board (PSAB) issued an amendment to the Introduction to Public Sector Accounting Standards of the PSA Handbook. This amendment eliminated the Government Business Type Organizations (GBTO) classification and entities currently classified as a GBTO are required to re-assess their classification.

Under the revised introduction, the Corporation is classified as an Other Government Organization (OGO). Effective for fiscal years beginning January 1, 2011, OGO's had to choose between International Financial Reporting Standards and standards issued by the PSAB. The Corporation determined the most appropriate basis of accounting to meet the needs of the users of its financial statements to be the standards issued by the PSAB. The Corporation will adopt the standards issued by the PSAB for its fiscal year beginning April 1, 2011, and is currently in the process of assessing the impact upon transition.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### *Property and equipment*

Property and equipment are recorded at cost and amortized over their estimated useful lives at the following rates and methods:

Computer equipment	30% declining balance
Equipment	20% declining balance
Furniture	20% declining balance

#### *Government assistance*

The portion of government assistance used for the acquisition of property and equipment is recorded as deferred government contributions and recognized as income on the same basis as the related assets are amortized. The operating portion of government assistance is recognized as income in the year received.

#### *Revenue recognition*

Rent revenue is recorded as earned and includes monthly rent from tenants. Business services revenue includes recoveries from tenants for utilities, photocopies, and other administrative services which are recorded as earned. Recoveries from tenants for improvements made to their premises are recorded as deferred leasehold contributions and amortized over the life of the lease.

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Notes to the Financial Statements

March 31, 2011

---

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### *Use of estimates*

In preparing these financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the period. Significant estimates in these financial statements include assessing the useful lives of property and equipment, payables and accrued liabilities. Actual results could differ from these estimates.

#### *Financial instruments*

The Corporation's financial assets and liabilities are generally classified and measured as follows:

<u>Financial asset/liability</u>	<u>Classification</u>	<u>Measurement</u>
Cash	Held for trading	Fair value
Receivables	Loans and receivables	Amortized cost
Payables and accruals	Other liabilities	Amortized cost

Held for trading financial assets are financial instruments purchased for resale, generally within a short period of time and other financial instruments that an entity designates on initial recognition as instruments that it will measure at fair value with changes in fair value recorded in net earnings.

Fair value is the estimated amount for which a financial investment could be exchanged between willing parties, based on the current market for instruments with the same risk, principal and remaining maturity. Due to the short period to maturity, the fair value of cash, receivables, and payables and accruals approximate their carrying values as presented in the balance sheet.

Loans and receivables and other financial liabilities are recorded at amortized cost using the effective interest method with gains and losses recognized in net earnings in the period that the asset or liability is derecognized or in the period that the asset is impaired.

Other financial liabilities are recorded at amortized cost using the effective interest method with gains and losses recognized in the income statement in the period that the liability is derecognized. Other liabilities include all liabilities other than held for trading liabilities. Transaction costs related to financial liabilities classified as other liabilities are expensed when incurred.



# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Notes to the Financial Statements

March 31, 2011

### 4. PROPERTY AND EQUIPMENT

	2011			2010
	Cost	Accumulated Amortization	Net Book Value	Net Book Value
Building improvements	\$ 631,752	\$ 631,752	\$ -	\$ -
Equipment	70,080	60,819	9,261	8,095
Computer equipment	38,772	38,037	735	1,051
Furniture	99,218	85,344	13,874	17,342
	<u>\$ 839,822</u>	<u>\$ 815,952</u>	<u>\$ 23,870</u>	<u>\$ 26,488</u>

### 5. RELATED PARTY TRANSACTIONS

Entity	Relationship	Purchases From	Year End Payable
Nova Scotia Innovation Corporation ("Innovacorp")	Sister	\$ 372,069	\$ 805,273

Transactions with these companies are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

The balance payable to Innovacorp is non-interest bearing and has arisen from cash advances to fund operations.

### 6. CAPITAL STOCK

	2011	2010
Authorized		
100,000 Common shares with no par value		
Issued and outstanding		
1 Common share	\$ 1	\$ 1

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Notes to the Financial Statements

March 31, 2011

### 7. FINANCIAL INSTRUMENTS

Financial instruments include the following:

	2011		2010	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Held for trading:				
Cash	\$ 30,515	\$ 30,515	\$ 44,731	\$ 44,731
Loans and receivables:				
Receivables	43,167	43,167	34,220	34,220
Other liabilities:				
Payables and accrued liabilities	17,258	17,258	25,598	25,598
Due to Innovacorp	805,273	805,273	538,077	538,077
	<u>\$ 896,213</u>	<u>\$ 896,213</u>	<u>\$ 642,626</u>	<u>\$ 642,626</u>

The carrying value of cash, receivables, payables and accrued liabilities, and due to Innovacorp approximate their fair value due to the short-term maturity of these instruments.

#### *Risks associated with financial assets and liabilities*

The Corporation is exposed to various financial risks arising from its financial assets and liabilities. These include liquidity risk and credit risk. To manage these risks, the Corporation limits its transactions to those in the nature of trade.

#### *Liquidity risk*

Liquidity risk is the risk that the Corporation will encounter difficulty in meeting its financial obligations. The Corporation believes it has access to sufficient sources of operating cash flows provided by its sister corporation, InNOVAcorp, and funding from the Province as required to meet its obligations as they become due.

The following table shows the timing of expected payments on current liabilities:

	Due within 1 Year
Payables and accruals	\$ 17,258
Due to Innovacorp	805,273

#### *Credit risk*

Credit risk refers to the risk that a counterparty will fail to fulfill its obligations under a contract and, as a result, will cause the Corporation to suffer a loss. The Corporation's financial assets that are exposed to credit risk consist primarily of accounts receivable.

# BIOSCIENCE ENTERPRISE CENTRE INCORPORATED

## Notes to the Financial Statements

March 31, 2011

---

### 7. FINANCIAL INSTRUMENTS (continued)

#### *Receivables*

Trade receivables are significantly concentrated with 100% of the balance due from tenants, several of whom are early stage technology based companies. The stage of development of the Corporation's client base combined with the technology sector concentration increases the associated credit risk. The Corporation's sister company Innovacorp's active involvement with the Corporation's tenants through the delivery of its High Performance Incubation services mitigates this risk. The maximum exposure to credit risk associated with financial assets is the total carrying value of those assets.

Details of trade receivables are as follows:

	<b>Current</b>	<b>Up to 90 Days Past Due</b>	<b>Over 90 Days Past Due</b>	<b>Allowance for Doubtful Accounts</b>	<b>Total</b>
Trade receivables	\$ 28,336	\$ 6,184	\$ 207,059	\$ (202,386)	\$ 39,193
HST Receivable	2,578	-	-	-	2,578
Other	1,397	-	-	-	1,397
	<b>\$ 32,311</b>	<b>\$ 6,184</b>	<b>\$ 207,059</b>	<b>\$ (202,386)</b>	<b>\$ 43,168</b>

### 8. ECONOMIC DEPENDENCE

Since commencing operations in 1999, the Corporation has operated as part of the Nova Scotia Innovation Corporation's ("Innovacorp") incubation activities. Innovacorp receives annual operating funding from the Province for its activities, including incubation, and has advanced funds to the Corporation to cover cash requirements in excess of other source revenue. The Corporation continues to be reliant on these advances from Innovacorp to meet its obligation.

### 9. SUBSEQUENT EVENTS

The operations of the Corporation have been relocated to leased premises in the Life Sciences Research Institute effective April 1, 2011 and have been assumed by Innovacorp at that date. The future of the Corporation will be determined in the 2011-12 fiscal year.

### 10. COMPARATIVE FIGURES

Certain of the comparative figures have been reclassified to conform to the current year's financial statement presentation.